Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Strategy execution – ensuring it all fits together

Effective brand strategies are like a well-made jigsaw but they can end up looking nothing like the picture that was agreed on

- PMLiVE

Successful Education at ESC

With World Heart Day just having passed (29th September), Medscape wants to take the opportunity to look back and recap what was accomplished at ESC 2024.  At this year’s event,...

Medscape Education

- PMLiVE

How women are revolutionising rare disease

Women have played a crucial role in rare disease awareness and better care, overcoming gender biases and systemic challenges to drive progress in this often-overlooked field.

Medscape Education

- PMLiVE

FDA approves IntraBio’s Aqneursa to treat Niemann-Pick disease type C patients

The rare lysosomal storage disorder affects approximately one in every 100,000 to 120,000 births

- PMLiVE

Roche’s injectable C5 inhibitor PiaSky recommended by NICE for rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately 1.59 per 100,000 people in the UK

- PMLiVE

Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension

Yuvanci is now the only single tablet combination therapy for PAH patients in Europe

- PMLiVE

‘Causes That Count, Health’ report – key issues affecting global health

The report focuses on the physical and mental health issues that matter most to people around the world

- PMLiVE

2024 updates to the ABPI Code of Practice Clause 12

Iain Shield (Associate Director – Market Access, Mtech Access) has reviewed the changes to the ABPI Code of Practice, and highlights updates to prescribing information (Clause 12) and considerations around...

Petauri Evidence

- PMLiVE

Gaps in obesity care and education

Yesterday marked World Heart Day, and Medscape is at the forefront with a featured article in Media Planet's cardiology campaign highlighting gaps in obesity care and education. This important piece...

Medscape Education

- PMLiVE

MHRA approves Pharming’s Joenja as first drug for rare immune disease APDS

Up to 40 people in the UK are affected by activated phosphoinositide 3-kinase delta syndrome

- PMLiVE

Ipsen’s Kayfanda granted EC approval to treat cholestatic pruritus in Alagille syndrome

The rare genetic disorder affects approximately three in every 100,000 births globally

- PMLiVE

British Skin Foundation receives £10,000 donation from Circle Health Group

The healthcare provider’s previous donation is supporting research into early melanoma detection

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links